UBS analyst Elizabeth Garcia maintains Repligen (NASDAQ:RGEN) with a Buy and lowers the price target from $205 to $185.
UBS Maintains Buy on Repligen, Lowers Price Target to $185
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.